Britain and America have finalized a landmark trade agreement that will ensure zero tariffs on UK pharmaceutical exports going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost spending on medicines through the NHS. This move secures that tariffs on these key goods will stay at nothing for a duration of 36 months.
This agreement comes after previous statements to dramatically increase tariffs on patented pharmaceutical imports, with potential rates mentioned reaching one hundred percent.
"This deal with the Britain bolsters the global environment for innovative medicines and establishes long-overdue balance to U.S.–U.K. medicine commerce," a statement declared.
Trade Significance
Pharmaceuticals are one of the UK's largest goods shipped to the US, which is easily the largest market for major UK drugmakers.
Trade data show that in the 12 months leading up to September, the UK shipped drugs valued at billions to the US. This amount represented 17.4% of total UK exports in that period.
"This agreement secures employment, stimulates investment and sets the stage for the UK to become a international leader for life sciences," a minister remarked.
Key British Pledges
The agreement involves several specific changes from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to raise total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at fifteen percent. In the past, rebates exceeded twenty percent.
Recent Tensions
The pact follows a protracted tension between the sector and the UK government over spending levels and approval rates.
These tensions were exacerbated by claims that American customers were charged several times more for the same drugs than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS must increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its resources over the past decade.
